HIV multiantigen vaccine (Bavarian Nordic)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameHIV multiantigen vaccine (Bavarian Nordic)
Drug Alias NameMVA-BN HIV multiantigen2E8 TCID50 MVA-mBN120BMVA-HIV multiantigen vaccine MVA-mBN120BMVA-mBN120B
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV InfectionsSexually Transmitted Diseases, Viral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesThailand
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBavarian Nordic A/S
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Pharmaceuticals Inc
Inactive CompaniesJanssen Vaccines & Prevention BvBavarian Nordic A/S
Active IndicationsAcquired Immunodeficiency SyndromeHIV InfectionsSexually Transmitted Diseases, Viral
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A